POS vs FLU for First Line Treatment of Coccidioidomycosis (Study P04558Am1)(COMPLETED)
Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety of posaconazole (POS) in the treatment of coccidioidomycosis. Period A
consisted of 2 blinded arms, posaconazole and fluconazole. Recruitment was stopped, and
participants in Period A may have been eligible to roll over to an open-label,
non-comparitive Period B. During Period B, participants received posaconazole for a treatment
duration not to exceed 12 months.